Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
6
Bullish
6
Bearish
17
Neutral
6
Bullish
23
Bearish
15
Neutral
0
Bullish
17
Discovery themes featuring this stock
Neogen Chemicals is an Indian specialty chemicals manufacturer focused on bromine‑based compounds, lithium salts, grignard reagents and CDMO/contract manufacturing, operating facilities at Mahape and Karakhadi while expanding operations at Dahej SEZ and via Neogen Ionics to address battery‑grade electrolyte and salt markets.
The company has pivoted decisively into battery materials via an 80/20 JV with Japan’s Morita, Pakhajan greenfield development and Dahej scale‑up to produce LiPF6 salts and formulated electrolytes, positioning Neogen as a non‑FEOC alternative to Chinese supply and benefiting from US 45X and India localization tailwinds.
Q3 FY26 delivered consolidated revenue of INR 220 crore (9% YoY) with gross profit up 13% and ~150 basis points margin expansion; EBITDA was INR 32 crore and PAT INR 4 crore, with near‑term margin pressure from Neogen Ionics ramp, fire‑related rebuilding costs, interim tolling expenses and higher finance costs despite insurance receipts totaling INR 83.48 crore to date.
Management is executing multiple financing flows: an in‑principle INR 150 crore promoter preferential allotment, expected $20 million Morita equity infusion for the JV, and anticipated insurance settlements (net receivable ~INR 251.12 crore) to collectively shore up liquidity and support capex and working capital for battery vertical scale‑up.
Operationally, Dahej replacement plant commissioning is on track for Q1 FY27, Neogen Ionics contributed INR 12 crore in Q3, Pakhajan trials and equipment assembly are underway with commercial electrolyte targeted H1 FY27 and salt targeted H2 FY27, and management is maintaining FY27 battery chemicals guidance of INR 400–500 crore.
Chemicals & Petrochemicals
Specialty Chemicals
5,650 Cr
Moderate Risk
196.5
44.1
-11.1
5.8
2,370.00
978.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1933.95 | 6,857 Cr | 24.66 | 2.50 | 1.14 | 9.74 | 12.15 | 6.90 | ||
557.00 | 6,848 Cr | 66.50 | 3.54 | 0.45 | 5.52 | 7.20 | 3.96 | ||
2063.65 | 5,650 Cr | 196.51 | 5.78 | 0.05 | 3.52 | 5.24 | 1.23 | ||
181.90 | 5,054 Cr | 63.30 | 2.55 | 0.16 | 4.00 | 4.35 | 2.30 | ||
1157.00 | 5,018 Cr | 15.23 | 2.26 | 0.43 | 14.94 | 14.69 | 9.47 | ||
39.62 | 4,614 Cr | 37.73 | 5.23 | 0.06 | 12.32 | 17.29 | 12.78 | ||
2455.00 | 4,327 Cr | 23.40 | 3.17 | 2.20 | 13.38 | 12.68 | 7.51 | ||
| Median: 7 Co. | — | 1157.00 | 5,054 Cr | 37.73 | 3.17 | 0.43 | 9.74 | 12.15 | 6.90 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Neogen Chemicals Ltd (NEOGEN) is currently trading at 2,063.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Neogen Chemicals is an Indian specialty chemicals manufacturer focused on bromine‑based compounds, lithium salts, grignard reagents and CDMO/contract manufacturing, operating facilities at Mahape and Karakhadi while expanding operations at Dahej SEZ and via Neogen Ionics to address battery‑grade electrolyte and salt markets. The company has pivoted decisively into battery materials via an 80/20 JV with Japan’s Morita, Pakhajan greenfield development and Dahej scale‑up to produce LiPF6 salts and formulated electrolytes, positioning Neogen as a non‑FEOC alternative to Chinese supply and benefiting from US 45X and India localization tailwinds. Q3 FY26 delivered consolidated revenue of INR 220 crore (9% YoY) with gross profit up 13% and ~150 basis points margin expansion; EBITDA was INR 32 crore and PAT INR 4 crore, with near‑term margin pressure from Neogen Ionics ramp, fire‑related rebuilding costs, interim tolling expenses and higher finance costs despite insurance receipts totaling INR 83.48 crore to date. Management is executing multiple financing flows: an in‑principle INR 150 crore promoter preferential allotment, expected $20 million Morita equity infusion for the JV, and anticipated insurance settlements (net receivable ~INR 251.12 crore) to collectively shore up liquidity and support capex and working capital for battery vertical scale‑up. Operationally, Dahej replacement plant commissioning is on track for Q1 FY27, Neogen Ionics contributed INR 12 crore in Q3, Pakhajan trials and equipment assembly are underway with commercial electrolyte targeted H1 FY27 and salt targeted H2 FY27, and management is maintaining FY27 battery chemicals guidance of INR 400–500 crore.
Over the past 52 weeks, Neogen Chemicals Ltd has traded between a low of ₹978.00 and a high of ₹2,370.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Neogen Chemicals Ltd has a market capitalization of approximately 5,649.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Neogen Chemicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 196.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,649.80 Cr, Neogen Chemicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Neogen Chemicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Neogen Chemicals Ltd is 196.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Consolidated revenue from operations was ₹250.29 crore and consolidated PAT was ₹17.11 crore in Q1 FY27.
Revenue from operations was ₹250.29 crore and PAT was ₹17.11 crore for Q1 FY27, up 34.04% and 66.76% year-on-year, respectively.
The Q1 FY27 earnings conference call is scheduled for Monday, July 27, 2026, at 4:00 PM IST.
Neogen Chemicals said it raised ₹161 crore by allotting 10,00,000 equity shares at ₹1,610 per share to Cadamba Solutions Private Limited.
Investor Presentation
Neogen Chemicals Ltd released Q1 FY27 earnings presentation: standalone revenue ₹252.3cr (+37%), consolidated revenue ₹250.3cr (+34%), strong EBITDA/PAT growth; Dahej plant rebuild complete; Board approved up to ₹600 crore QIP.
Financial Results
Neogen Chemicals reports Q1 FY27 consolidated revenue ₹250 crore (+34% YoY), EBITDA ₹48 crore (+53%), PAT ₹17 crore (+67%); EPS ₹6.29. Board approved QIP up to ₹600 crore. Dahej plant reconstruction complete; trial runs underway.
Financial Results
Neogen Chemicals Ltd: Board approved unaudited standalone & consolidated results for quarter ended June 30, 2026; convened 37th AGM on 2026-08-21; record date 2026-08-13; book closure 2026-08-14 to 2026-08-21; in-principle approval to raise up to ₹600 crore.
Financial Results
Neogen Chemicals Ltd approved unaudited standalone & consolidated results for quarter ended 30-Jun-2026; approved FY25-26 integrated annual report; AGM on 2026-08-21 (VC); record date 2026-08-13; book closure 2026-08-14 to 2026-08-21; in-principle approval to raise up to ₹600 crore; appointment of internal auditor.
Regulatory/Compliance Filing
Neogen Chemicals Ltd files Statement under Reg 32 for quarter ended 2026-06-30 and CRISIL monitoring report, confirming no deviation/variation in utilisation of proceeds from the preferential issue.
Regulatory/Compliance Filing
Neogen Chemicals Ltd files Regulation 32 statement and CRISIL monitoring agency report for quarter ended 2026-06-30; audit committee reviewed on 2026-07-24 and confirms no deviation/variation in utilisation of proceeds from preferential issue.
